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Background: Latent reservoirs of HIV-1 provide a major challenge to its cure. There are increasing reports of
interplay between HIV-1 replication and host miRNAs. Several host miRNAs, which potentially target the nef-3′LTR
region of HIV-1 RNA, including miR-29a, are proposed to promote latency.
Findings: We used two established cellular models of HIV-1 latency – the U1 monocytic and J1.1 CD4+ T cell lines
to show an inverse relationship between HIV-1 replication and miR-29a levels, which was mediated by the HIV-1
Nef protein. Using a miR-29a responsive luciferase reporter plasmid, an expression plasmid and an anti-miR29a LNA,
we further demonstrate increased miR-29a levels during latency and reduced levels following active HIV replication.
Finally, we show that miR-29a levels in the PBMCs and plasma of HIV infected persons also correlate inversely with
latency and active viral replication.
Conclusions: The levels of miR-29a correlate inversely with active HIV-1 replication in cell culture models and in HIV
infected persons. This links miR-29a to viral latency and suggests another approach to activate and destroy latent
HIV-1 reservoirs.
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MicroRNAs (miRNAs) are 18–23 nucleotides non-coding,
regulatory RNA molecules, which are involved in post-
transcriptional gene regulation and have recently been
shown to be important for regulating host responses in
vertebrates [1]. During viral infections, miRNAs can ei-
ther directly affect viral replication or modulate the ex-
pression of host genes and pathways essential for it [2].
For example, miR-32 and miR-181 restrict the replication
of primate foamy virus 1 replication [3], and porcine re-
productive and respiratory syndrome virus and Mink
enteritis virus [4,5], respectively. Alternatively, miR-122
is highly expressed in the liver and facilitates hepatitis
C virus replication [3,6]. The human immunodeficiency
virus (HIV) may also be targeted by several host miRNAs* Correspondence: jameelshahid@gmail.com
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unless otherwise stated.[7]. The HIV-1 Tat and Nef proteins inhibit key compo-
nents of the host miRNA pathway [8,9], knockdown of
the miRNA biogenesis proteins Drosha and Dicer in la-
tently infected cells increases HIV-1 replication, and host
miRNAs such as the miR-17/92 cluster indirectly modu-
late HIV-1 replication through the p300/CBP-associated
factor [10]. Thus, there is significant functional inter-
play between HIV-1 and miRNA-mediated silencing in
host cells.
Following highly active antiretroviral therapy (HAART),
the HIV-1 load is reduced dramatically to undetectable
levels. However, replication competent viruses survive in
latent reservoirs whose size is determined by the initial
viral loads. On therapy interruption or failure, the virus
replicates and repopulates peripheral sites [11]. The ability
of HIV-1 to cause latent and persistent infection is a major
impediment to its cure, making it important to under-
stand the mechanisms of latency [12]. Profiling studies
using various HIV-1 infection models have revealed diffe-
rent miRNAs associated with viral replication [13-16]. Al-
though their contribution to HIV-1 latency is unclear,
comparative miRNA expression in resting versus activatedd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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miRNAs, which potentially target the nef-3′UTR region
to promote latency [17]. Several recent studies have shown
that miR-29a, which targets the nef-3′UTR, is a potent in-
hibitor of HIV-1 replication [15,18,19]. Another report
also showed miR-29a, −29b, −9 and -146a to target the
SIV/HIV 3′UTR [20]. We hypothesize that miR-29a levels
are high during latency and are reduced during active viral
replication, and have explored this with cellular models of
latent HIV-1 infection as well as PBMC and plasma from
HIV infected individuals. All cell lines, other materials and
methods used are detailed in Additional file 1: Materials
and Methods.
We used two well-established cell culture models of
latent HIV-1 infection. These include U1, a derivative of
U937 human monocytic cells and J1.1, derived from
CD4+ Jurkat T cells [21,22]. Both these cell lines produceFigure 1 MiR-29a levels are inversely correlated with activation in cel
U1 cells and J1.1 cells were activated with PMA, RNA was isolated and qua
cells were treated with vehicle (DMSO) or PMA, and western blotting of ce
carried out with anti-p24 antibody. (C) U937 and Jurkat cell lines were activ
described in Materials and Methods. (D) U937 cells or stable U937 cell lines
quantifying miR-29a levels. Western blotting of the indicated cell lysates wa
three independent experiments; *p < 0.05.low basal levels of HIV-1, which is increased several
folds on activation with phorbol myristic acid (PMA).
If our hypothesis is correct, miR-29a levels should be
high in the basal state when HIV-1 replication is low,
but should decrease with PMA activation. Quantitative
RT-PCR (qRT-PCR) showed this to be the case in U1
and J1.1 cells (Figure 1A). PMA activation also resulted
in robust increase in virus production (Figure 1B). How-
ever, PMA activation of U937 or Jurkat cells did not re-
duce miR-29a levels (Figure 1C), suggesting that viral
replication, but not activation per se is important for
this effect. Being an early response, miR-29a levels may
be modulated by a viral protein expressed early in the
replication cycle. Since a large majority of early viral
transcripts encode the Nef accessory protein [23], we
quantified the levels of miR-29a in U937 cells that stably
expressed this protein [24]. Compared to control cells,lular models of HIV latency. (A) The two cellular models of latency –
ntified for miR-29a levels as described in Materials and Methods. (B) U1
ll lysates (upper panel) and culture supernatants (lower panel) was
ated with PMA, RNA was isolated and quantified for miR-29a levels as
expressing either the HIV-1 Nef or Vpu protein were also used for
s carried out using anti-GFP antibodies. All data represents at least
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levels of miR-29a (Figure 1D). However, U937 cells stably
expressing Vpu [25], an accessory protein expressed late
in infection, showed no significant changes in miR-29a
levels (Figure 1D).
We then used the pMIR-Report-Nef3′UTR reporter
plasmid, which contains the HIV-1 nef-3′UTR cloned
downstream of the luciferase gene and is responsive to
varying levels of miR-29a [18]. The pMIR-Report-Nef3′
UTR or the control pMIR-Report constructs were trans-
fected in U1 and J1.1 cells and the luciferase activities
were measured. Following PMA activation, there was a
significant increase in luciferase activity in pMIR-Report-
Nef3′UTR transfected U1 and J1.1 cells (Figure 2A). This
correlated with reduced miR-29a levels following HIV-1
activation. The J1.1 cells were then transfected with theFigure 2 Functional correlation between miR-29a levels and HIV repli
Report-Nef3′UTR reporter plasmid or the control pMIR-Report plasmid toge
and the cell lysates quantified for luciferase activity as described in Materia
relative to unactivated cells after two normalizations - one with the Renilla
with luciferase activity observed with the control plasmid. Data represents thr
with the miR-29a-EGFP or EGFP expression vector. After 48 hr the cells were a
was measured using a quantitative p24 ELISA. Transfection efficiency was arou
independent experiments; the p-values for different sets are indicated. (C) U1
After 48 hr HIV-1 production in culture supernatants was measured using a q
represent three independent experiments; *p < 0.05. The western blot sho
loading control.pEGFP-miR-29a (or control pEGFP) expression plasmid
and p24 levels were estimated in the culture medium. In
miR-29a over-expressing J1.1 cells whether activated with
PMA or not, p24 levels were reduced by ~60% compared
to cells transfected with the control vector (Figure 2B).
Finally, we reduced miR-29a levels in U1 cells with an
anti-miR-29a LNA as described previously [18] and found
increased virus levels in the culture supernatants and in
cells (Figure 2C).
In HIV infected but asymptomatic persons, the plasma
viral load is detectable and absolute CD4 counts are
high. In transition from the asymptomatic to symptom-
atic phase, HIV replicates actively leading to high viral
loads and depletion of CD4+ T cells. In patients on an-
tiretroviral therapy (ART), the plasma viral load goes
down below detection limits (<50 copies of viral RNAcation. (A) U1 cells and J1.1 cells were transfected with the pMIR-
ther with plasmid pRLTK. After 48 hr the cells were activated with PMA
ls and Methods. The luciferase activity in PMA activated cells is shown
luciferase activity to control for transfection efficiency and the other
ee independent experiments; *p < 0.05. (B) J1.1 cells were transfected
ctivated with PMA (or not) and HIV-1 production in culture supernatants
nd 30-40%. Data are shown as ng/ml of p24 and represent three
cells were transfected with a miR-29a specific LNA or a control LNA.
uantitative p24 ELISA. Data are shown relative to the EGFP control and
ws intracellular levels of Gag for the same cells; Actin was used as a
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continue to exist. In patients who discontinue ART or
who fail on ART due to drug resistant mutations, the
virus replicates rapidly leading to detectable plasma levels.
We used a cohort of HIV-1 infected individuals who were
categorized into either asymptomatic or symptomatic
groups based on their CD4+ T cell counts, and quanti-
fied miR-29a levels in their PBMCs and plasma. The
miR-29a levels were higher in PBMCs from asymptomatic
persons in whom virus replication is restricted, compared
to symptomatic patients in whom there is active viral rep-
lication (Figure 3A). This pattern of miR-29a expression
was also observed in the plasma of asymptomatic and
symptomatic patients (Figure 3B). We noted that miR-29a
levels in PBMCs of healthy persons were higher than in
HIV-infected persons, but the plasma levels of miR-29a
showed an opposite trend (Figure 3A, B). Multiple tissues
and cell types contribute the miR-29a in plasma, the regu-
lation of which following HIV infection is poorly under-
stood. We also observed recently that cellular levels of a
given miRNA do not necessarily correlate with its secreted
levels; some miRNAs are selectively retained in cells while
others are preferentially secreted [26].
Previous studies on the role of miRNAs in HIV infec-
tion and pathogenesis have largely focused on acute in-
fection models that involve actively replicating virus.
Microarray analysis of acutely infected PBMCs showed
downregulation of miR-29a and similar results were ob-
served in PBMCs isolated from HIV infected individualsFigure 3 MiR-29a levels in HIV-infected persons correlate with diseas
groups – asymptomatic and symptomatic based on their CD4 counts. (A) P
quantified for miR-29a levels as described in Materials and Methods. The no
values are shown.with high viral load [15,16]. These results directly sup-
port our hypothesis. In the U1 and J1.1 latency models
we observed miR-29a levels to reduce following PMA
activation and HIV-1 replication, and this correlated with
expression of the Nef protein. Higher levels of miR-29a in
the PBMCs and plasma of HIV-infected asymptomatic in-
dividuals compared to those with symptomatic disease,
also support a role for miR-29a in HIV latency. Whether
the size of the latent reservoir is determined early in infec-
tion or is related to peak viral loads or CD4/CD8 ratio is
currently debatable. Our data support its relation to viral
load, which is lower in asymptomatic individuals.
A functional miR-29a site is located in a highly con-
served region within the HIV-1 nef-3′UTR. Previous stu-
dies have shown that co-transfection of HeLa cells with
the HIV-1 pNL4-3 infectious clone and a miR-29a mimic
leads to reduced p24 levels [15,18]. In physiologically rele-
vant cell line models, we observed that overexpression of
miR-29a further reduced HIV-1 replication, and a knock-
down of miR-29a induced HIV-1 replication in latently in-
fected cells without the need for PMA. Previous studies
have shown that HIV-1 latency is controlled at the tran-
scriptional level, and histone deacetylase (HDAC) inhibi-
tors have been studied to break HIV-1 latency. Different
HDAC inhibitors can induce HIV-1 replication from 2–20
folds in U1 cells [27]. Though the effects of blocking
miR-29a on HIV-1 replication are small compared to
those of HDAC inhibitors, these are still significant. Our
findings suggest that HIV-1 latency may also be controllede stage. A cohort of HIV-infected persons was categorized into two
BMCs and (B) plasma from this cohort as well as healthy persons were
rmalized 1/Ct values are plotted for each individual sample. The p
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nity for synergism with HDAC inhibitors in purging viral
reservoirs.
The interaction of miR-29a and 3′UTR of HIV-1 RNA
is sufficient for targeting the latter to the P bodies; the
disruption of P bodies results in enhanced viral repli-
cation [19]. Host or environmental cues might release
viral mRNAs from P bodies and thus release the sup-
pression on viral replication [19]. Along these lines, in-
creased miR-29a might target more viral mRNAs to P
bodies and promote latency. The present study shows
that HIV-1 Nef and miR-29a levels are inversely corre-
lated, suggesting another mechanism for its activation
of HIV-1 replication. Our data also suggest a role for
miR-29a in maintaining HIV-1 latency and provides a
new approach to activate (and destroy) latent HIV-1
reservoirs by inhibiting miR-29a. Further investigations
are required to understand the tripartite regulatory axis
of Nef, miR-29a and latency.
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